DRES-10. DRD5 IS A MODULATOR OF GLIOMA SUSCEPTIBILITY TO DRD2 ANTAGONISM BY ONC201

ONC201 is the first selective antagonist of dopamine receptor D2 (DRD2) and D3 (DRD3) for clinical oncology that has exhibited preliminary clinical activity in high grade gliomas. We investigated DRD2 dysregulation in glioma and its role in ONC201 efficacy. Investigating CRISPR screens across a spec...

Full description

Saved in:
Bibliographic Details
Published in:Neuro Oncol
Main Authors: Vijay Prabhu, Varun, Madhukar, Neel, Gilvary, Coryandar, Kline, C Leah B, Tarapore, Rohinton, El-Deiry, Wafik, Doherty, Faye, VanEngelenburg, Alexander, Durrant, Jessica, Benes, Cyril, Oster, Wolfgang, Elemento, Olivier, Allen, Joshua
Format: Artigo
Language:Inglês
Published: Oxford University Press 2018
Subjects:
Abstracts
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216484/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.317
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items